Sign In
Buy IDXG
$1.75
-0.0100 (-0.568%)
At Close: Jun 03, 2026
Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®
04:05pm, Monday, 05'th Apr 2021
Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contracto
Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results
05:20pm, Wednesday, 31'st Mar 2021
PARSIPPANY, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended Decem
Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR
07:30am, Wednesday, 17'th Mar 2021
Part of Company's Site Consolidation and Cost Savings Measures
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois
04:31pm, Thursday, 25'th Feb 2021
In-network status for ThyGeNEXT® and ThyraMIR® with State's Largest Payer
Interpace Biosciences Announces Acceptance for Trading on the OTCQX
05:54pm, Wednesday, 24'th Feb 2021
PARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, to
Interpace Biosciences Announces Path Forward in Letter to Shareholders
09:21pm, Tuesday, 16'th Feb 2021
PARSIPPANY, NJ, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized medicine, issued the following communication to shareh
Interpace Biosciences Announces CFO Leadership Transition
04:42pm, Thursday, 04'th Feb 2021
PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors h
Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital
09:27am, Monday, 01'st Feb 2021
Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New Jersey,
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Florida
09:15am, Thursday, 28'th Jan 2021
In-network status for ThyGeNEXT® and ThyraMIR® with State's Largest Payer
Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021
03:38pm, Wednesday, 20'th Jan 2021
PARSIPPANY, NJ, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that it will hold its third quarter 2020 financial results conference call and webcast afte
Interpace Biosciences Announces Third Quarter 2020 Financial and Business Results and Completion of $5 Million Bridge Loan
08:30am, Wednesday, 20'th Jan 2021
Conference Call and Webcast Thursday January 21, 2021 at 4:30 pm ET
Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective December 31, 2
Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing
04:11pm, Thursday, 19'th Nov 2020
PARSIPPANY, NJ, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on November 18, 2020 received notice from the Listing Qualifications
Interpace Biosciences (NASDAQ:IDXG) Shares Gap Up to $2.98
06:42am, Friday, 16'th Oct 2020
Interpace Biosciences, Inc. (NASDAQ:IDXG) shares gapped up prior to trading on Wednesday . The stock had previously closed at $2.98, but opened at $3.56. Interpace Biosciences shares last traded at $4
Brokerages Anticipate Interpace Diagnostics Group Inc (NASDAQ:IDXG) to Post -$1.64 Earnings Per Share
08:02am, Friday, 28'th Aug 2020
Wall Street analysts forecast that Interpace Diagnostics Group Inc (NASDAQ:IDXG) will post earnings of ($1.64) per share for the current quarter, according to Zacks. Two analysts have issued estimates
